. Author manuscript; available in PMC: 2014 Nov 4.

Published in final edited form as: Mol Pharm. 2013 Oct 21;10(11):4099–4106. doi: 10.1021/mp4005468

Table 1.

Live enzymalogy and hemocompatibility of nanovectors in mice treated with NP-pArg-siRNA, NP-PEI-siRNA, and PBS as a control.

Test	Units	PBS (mean ± s.d.)	NP-pArg- siRNA (mean ± s.d.)	NP-PEI-siRNA (mean ± s.d.)	Normal (mean range)
AST	U/L	200.0 ± 164.6	72.9 ± 11.1	2455 ± 222	49.6–171.2
ALT	U/L	38.3 ± 12.5	43.5 ± 12.0	591 ± 88	14.1–110.7
WBC	× 10³/μL	7.63 ± 2.63	4.56 ± 0.58	4.57 ± 0.32	3.56–10.29
Hemolysis	+/−^a	− − −	− − −	+ + +

(+/−) indicate number of mice positive (+) or negative (−) for hemolysis.